These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 608570)

  • 21. Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones.
    Iwamura K
    Tokai J Exp Clin Med; 1982 Nov; 7(6):671-83. PubMed ID: 7184199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleation time of gall bladder bile in gall stone patients: influence of bile acid treatment.
    Sahlin S; Ahlberg J; Angelin B; Reihnér E; Einarsson K
    Gut; 1991 Dec; 32(12):1554-7. PubMed ID: 1773966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of response to ursodeoxycholic acid for gallstone dissolution.
    Bateson MC; Hill A; Bouchier IA
    Digestion; 1980; 20(5):358-64. PubMed ID: 7390061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Oral dissolving treatment of gallbladder calculi: focus in 1989].
    Erlinger S
    Ann Chir; 1989; 43(6):417-9. PubMed ID: 2817740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
    Maton PN; Murphy GM; Dowling RH
    Gut; 1980 Dec; 21(12):1082-6. PubMed ID: 7461467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.
    Iser JH; Sali A
    Drugs; 1981 Feb; 21(2):90-119. PubMed ID: 7009140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.
    Iser JH; Maton PN; Murphy GM; Dowling RH
    Br Med J; 1978 Jun; 1(6126):1509-12. PubMed ID: 656777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Best-buy regimen of ursodeoxycholic acid for patients with gallstones.
    Lanzini A; Facchinetti D; Pigozzi MG; Bettini L; Muiesan G
    Scand J Gastroenterol; 1991 May; 26(5):551-6. PubMed ID: 1871547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Faecal bile acid loss and bile acid pool size during short-term treatment with ursodeoxycholic and chenodeoxycholic acid in patients with radiolucent gallstones.
    Salvioli G; Salati R
    Gut; 1979 Aug; 20(8):698-704. PubMed ID: 488763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Final outcome of ursodeoxycholic acid treatment in 126 patients with radiolucent gallstones.
    Gleeson D; Ruppin DC; Saunders A; Murphy GM; Dowling RH
    Q J Med; 1990 Jul; 76(279):711-29. PubMed ID: 2217675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical dissolution of gallstones by ursodeoxycholic acid: a clinical trial on 14 patients.
    Lin JT; Wang JT; Wang TH; Su CT
    Taiwan Yi Xue Hui Za Zhi; 1989 Apr; 88(4):370-6. PubMed ID: 2794937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ursodeoxycholic acid for adjuvant therapy with extracorporeal shock wave lithotripsy of gallstones.
    Fromm H
    J Clin Gastroenterol; 1988; 10 Suppl 2():S18-21. PubMed ID: 3062080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of diet on bile acid kinetics and biliary lipid secretion in gallstone patients treated with ursodeoxycholic acid.
    Frenkiel PG; Lee DW; Cohen H; Gilmore CJ; Resser K; Bonorris GG; Marks JW; Schoenfield LJ
    Am J Clin Nutr; 1986 Feb; 43(2):239-50. PubMed ID: 3004189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy.
    Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1984 Feb; 27(2):95-131. PubMed ID: 6365507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group.
    Petroni ML; Jazrawi RP; Pazzi P; Lanzini A; Zuin M; Pigozzi MG; Fracchia M; Galatola G; Alvisi V; Heaton KW; Podda M; Northfield TC
    Aliment Pharmacol Ther; 2001 Jan; 15(1):123-8. PubMed ID: 11136285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiolucent gallstone dissolution with bedtime UDCA administration.
    Conte D; Bozzani A; Sironi L; Rocca F; Camassa L; Bianchi PA
    Digestion; 1981; 22(6):302-4. PubMed ID: 7333417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursodeoxycholic acid for the dissolution of radiolucent gall bladder stones.
    Neligan P; Bateson MC; Trash DB; Ross PE; Bouchier IA
    Digestion; 1983; 28(4):225-33. PubMed ID: 6671484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with ursodeoxycholic acid alone.
    Podda M; Zuin M; Battezzati PM; Ghezzi C; de Fazio C; Dioguardi ML
    Gastroenterology; 1989 Jan; 96(1):222-9. PubMed ID: 2642440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase in serum total cholesterol and low-density lipoprotein cholesterol by high-dose chenodeoxycholic acid in patients with radiolucent gallstones significantly reversed during preventive low dose after gallstone dissolution.
    Pérez-Aguilar F; Bretó M; Alegre B; Berenguer J
    Digestion; 1985; 31(4):225-33. PubMed ID: 4007294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
    Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
    Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.